GLP-1 maintenance strategies: what the evidence says about staying off medication

What did @mariahhopkins_ actually say?

She said she has zero interest in trying retatrutide (reda) after 19 months on semaglutide and nine months on tirzepatide. Her reasoning is based almost entirely on anecdote: she has "talked to so many people" who switched from tirzepatide to retatrutide and "hated it," reporting worse appetite suppression, returning inflammation, and diminished mental health benefits. She also briefly addressed the muscle-preservation argument for retatrutide, arguing that protein intake and strength training matter more than which GLP-1 you are on.

To her credit, she frames this as personal preference and says people who love retatrutide should keep using it. That is a more responsible framing than most GLP-1 content on TikTok manages.

Does the science back this up?

Partially, but the comparison she is drawing does not yet have robust head-to-head clinical data behind it. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. In phase 2 trials (Jastreboff et al., 2023, NEJM), it produced weight loss of up to 24.2% at 48 weeks at the highest dose, exceeding tirzepatide's SURMOUNT-1 numbers on paper. On raw efficacy, retatrutide is not obviously inferior to tirzepatide.

The mental health and inflammation claims are based on anecdote, not published comparative data. GLP-1 receptors are expressed in the brain, and there is emerging research on neuroinflammation and mood (Mansur et al., 2023, CNS Drugs), but no published trial has directly compared tirzepatide and retatrutide on psychiatric outcomes. Her inflammation comparison is mechanistically plausible but speculative as stated.

What did they get wrong (or right)?

She got the muscle point mostly right. The concern that GLP-1 agonists can accelerate lean mass loss alongside fat loss is real and documented. Analyses from STEP trials (Wilding et al., 2021, NEJM) and SURMOUNT-1 (Jastreboff et al., 2022, NEJM) show a meaningful portion of weight lost on these drugs is lean mass. The fix, as she correctly states, is resistance training and adequate protein, regardless of which agent you are on.

Where she goes wrong is in treating anecdotal reports as a reliable basis for comparing two drugs. Switching experiences are confounded by dose, duration, individual pharmacogenomics, and expectations. People who switch and do fine tend not to post about it. That is textbook selection bias. Her conclusion is not necessarily wrong, but her evidence base is not strong enough to generalize to others.

What should you actually know?

Retatrutide has not received FDA approval as of mid-2025. Anything marketed as retatrutide outside a clinical trial is compounded or unapproved. Compounded versions are not equivalent to investigational or future brand-name drugs, and their purity and dosing consistency are not federally verified.

If you are stable on tirzepatide and doing well, the evidence does not support switching just because a newer agent produced higher average weight loss in a phase 2 trial. Phase 2 results frequently outperform real-world outcomes. If you are not getting adequate results on your current GLP-1, retatrutide's glucagon receptor activity may offer a different metabolic profile worth discussing with a provider. That is a clinical conversation, not a TikTok one.

Her personal choice to stay on tirzepatide is reasonable. Her framing of anecdotes as evidence for a broad conclusion about retatrutide being worse is not.